Autoreactive CD4 Tscm Development in Type 1 Diabetes

1 型糖尿病中自身反应性 CD4 Tscm 的发展

基本信息

项目摘要

PROJECT SUMMARY Autoimmune type 1 diabetes (T1D) results from T cell-mediated destruction of pancreatic beta cells in the islet, leading to lifelong dependence on exogenous insulin and risk of life-threatening glycemic events. As a result, deletion or immune deviation of islet-autoreactive T cells is a major therapeutic goal in the prevention and treatment of T1D. The existence of memory T cells with stem cell properties (Tscm) raises the possibility that they serve as an ongoing reservoir of autoreactive T cells in T1D. However, little is known about the presence of islet-specific CD4 Tscm cells in T1D. We have made the novel observation that there is an increased frequency of Tscm within the CD4 T cell compartment in peripheral blood from T1D patients compared with healthy donors (HD). Importantly, we also detected increased islet-specific CD4 T cells with a Tscm phenotype in the peripheral blood of T1D subjects relative to HD, both immediately and up to 7 years following diagnosis. Transcript analysis of islet-specific CD4 T cells showed increased expression of TCR, Wnt-β-catenin, and IL-7 signaling gene sets in cells from T1D subjects compared to HD, pathways known to play a central role in CD4 Tscm development. Further study is required to confirm that islet-specific CD4 Tscm in T1D have functional Tscm properties and to determine the mechanism leading to increased Tscm cell frequency in T1D. We hypothesize that islet-specific CD4 Tscm in T1D have the capacity for self-renewal and differentiation into central and effector memory T cells, and are increased in T1D due to elevated TCR, Wnt-β-catenin, and/or cytokine signaling. We will address our hypothesis in two specific aims. Aim 1 will investigate whether islet-specific CD4 Tscm cells in T1D subjects have phenotypic and functional properties of a memory stem cell population. We will evaluate the transcript profile, telomere length, survival, and the potential for self-renewal and differentiation of islet-specific CD4 Tscm compared to total CD4 naïve, Tscm, central memory (Tcm) and effector memory (Tem) populations in peripheral blood from T1D patients. The characteristics of CD8 Tscm cells will serve as a reference. As a control for disease, we will compare transcript profiles and function of total CD4 naïve, Tscm, Tcm, and Tem populations in peripheral blood from matched HD. Aim 2 will test the hypothesis that signaling pathways supporting the development of CD4 Tscm are elevated in T1D subjects versus HD, contributing to increased islet-specific CD4 Tscm cells in T1D. We will compare TCR, Wnt-β-catenin, and IL-7R pathway expression and signaling in CD4 naïve T cells from T1D subjects and HD. In parallel, we will determine if these pathways contribute to superior differentiation or survival of CD4 Tscm cells in T1D subjects vs. HD in response to islet peptides or polyclonal stimulation in the presence or absence of Wnt inhibitors/agonists and IL-7. The proposed study is appropriate for the R21 mechanism because it is an exploratory investigation of a novel autoreactive cell type in T1D. The results will open new areas of inquiry for targeting autoreactivity to prevent and treat T1D.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KAREN M CEROSALETTI其他文献

KAREN M CEROSALETTI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KAREN M CEROSALETTI', 18)}}的其他基金

HIPC U19 Adaptive Immunophenotyping Core
HIPC U19 适应性免疫表型核心
  • 批准号:
    10598125
  • 财政年份:
    2022
  • 资助金额:
    $ 26万
  • 项目类别:
Autoreactive CD4 Tscm Development in Type 1 Diabetes
1 型糖尿病中自身反应性 CD4 Tscm 的发展
  • 批准号:
    10680590
  • 财政年份:
    2022
  • 资助金额:
    $ 26万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 26万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 26万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 26万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 26万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 26万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 26万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 26万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 26万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了